Nasdaq Regulation



Eun Ah ChoiSenior Vice President
U.S. Listing Qualifications & Market Surveillance

March 16, 2023

Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

Division of Corporation Finance:

This is to certify that on March 16, 2023, The Nasdaq Stock Market LLC (the "Exchange") received from Ambrx Biopharma Inc. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following securities:

Ordinary Shares, par value US \$0.0001 per share

American depositary shares, each representing 7 ordinary shares, par value US \$0.0001 per share

We further certify that the security described above has been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking immediate acceleration of the effective date of registration, and we hereby join in such request.

Sincerely,

En Sh Chri